Psychopharmacology of affective disorders in the 21st century

Charles Nemeroff, Reunette W. Harris

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Over the past several years, remarkable advances have been made both in our understanding of the central nervous system (CNS) and in the pathophysiology of the major psychiatric disorders, resulting in major breakthroughs in our capacity to treat these devastating illnesses. Since the seminal work of Ramon Y Cajal and Golgi at the turn of the century, new techniques such as fluorescence histochemistry have evolved into immunohistochemical and more recently in situ hybridization. These techniques have permitted, for the first time, the elucidation of chemically defined neural circuits. Such advances in the mapping of neural systems and the visualization of monoaminergic and peptidergic neurons and their receptors in tissue sections have provided the tools for the burgeoning field of neurochemical pathology of psychiatric disorders. Data provided from such studies has served as the basis for the development of novel pharmacological approaches to the treatment of affective and anxiety disorders, as well as schizophrenia. This review focuses on two major neural systems implicated in the pathophysiology of depression, serotonin and corticotropin-releasing factor (CRF). Development of novel agents are described including selective serotonin receptor agonists, combined selective serotonin receptor antagonists and serotonin reuptake inhibitors, CRF receptor antagonists, and the use of an antisense strategy.

Original languageEnglish
Pages (from-to)517-525
Number of pages9
JournalBiological Psychiatry
Volume44
Issue number7
DOIs
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Psychopharmacology
Mood Disorders
Psychiatry
Corticotropin-Releasing Hormone Receptors
Serotonin Receptor Agonists
Serotonin Antagonists
Corticotropin-Releasing Hormone
Serotonin Uptake Inhibitors
Anxiety Disorders
In Situ Hybridization
Serotonin
Schizophrenia
Central Nervous System
Fluorescence
Pharmacology
Depression
Pathology
Neurons

Keywords

  • Antisense
  • Corticotropin-releasing factor (CRF)
  • Depression
  • Norepinephrine
  • Serotonin

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Psychopharmacology of affective disorders in the 21st century. / Nemeroff, Charles; Harris, Reunette W.

In: Biological Psychiatry, Vol. 44, No. 7, 01.10.1998, p. 517-525.

Research output: Contribution to journalArticle

Nemeroff, Charles ; Harris, Reunette W. / Psychopharmacology of affective disorders in the 21st century. In: Biological Psychiatry. 1998 ; Vol. 44, No. 7. pp. 517-525.
@article{9edf458619bd439b82d3f40b1a904a92,
title = "Psychopharmacology of affective disorders in the 21st century",
abstract = "Over the past several years, remarkable advances have been made both in our understanding of the central nervous system (CNS) and in the pathophysiology of the major psychiatric disorders, resulting in major breakthroughs in our capacity to treat these devastating illnesses. Since the seminal work of Ramon Y Cajal and Golgi at the turn of the century, new techniques such as fluorescence histochemistry have evolved into immunohistochemical and more recently in situ hybridization. These techniques have permitted, for the first time, the elucidation of chemically defined neural circuits. Such advances in the mapping of neural systems and the visualization of monoaminergic and peptidergic neurons and their receptors in tissue sections have provided the tools for the burgeoning field of neurochemical pathology of psychiatric disorders. Data provided from such studies has served as the basis for the development of novel pharmacological approaches to the treatment of affective and anxiety disorders, as well as schizophrenia. This review focuses on two major neural systems implicated in the pathophysiology of depression, serotonin and corticotropin-releasing factor (CRF). Development of novel agents are described including selective serotonin receptor agonists, combined selective serotonin receptor antagonists and serotonin reuptake inhibitors, CRF receptor antagonists, and the use of an antisense strategy.",
keywords = "Antisense, Corticotropin-releasing factor (CRF), Depression, Norepinephrine, Serotonin",
author = "Charles Nemeroff and Harris, {Reunette W.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0006-3223(98)00068-7",
language = "English",
volume = "44",
pages = "517--525",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Psychopharmacology of affective disorders in the 21st century

AU - Nemeroff, Charles

AU - Harris, Reunette W.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Over the past several years, remarkable advances have been made both in our understanding of the central nervous system (CNS) and in the pathophysiology of the major psychiatric disorders, resulting in major breakthroughs in our capacity to treat these devastating illnesses. Since the seminal work of Ramon Y Cajal and Golgi at the turn of the century, new techniques such as fluorescence histochemistry have evolved into immunohistochemical and more recently in situ hybridization. These techniques have permitted, for the first time, the elucidation of chemically defined neural circuits. Such advances in the mapping of neural systems and the visualization of monoaminergic and peptidergic neurons and their receptors in tissue sections have provided the tools for the burgeoning field of neurochemical pathology of psychiatric disorders. Data provided from such studies has served as the basis for the development of novel pharmacological approaches to the treatment of affective and anxiety disorders, as well as schizophrenia. This review focuses on two major neural systems implicated in the pathophysiology of depression, serotonin and corticotropin-releasing factor (CRF). Development of novel agents are described including selective serotonin receptor agonists, combined selective serotonin receptor antagonists and serotonin reuptake inhibitors, CRF receptor antagonists, and the use of an antisense strategy.

AB - Over the past several years, remarkable advances have been made both in our understanding of the central nervous system (CNS) and in the pathophysiology of the major psychiatric disorders, resulting in major breakthroughs in our capacity to treat these devastating illnesses. Since the seminal work of Ramon Y Cajal and Golgi at the turn of the century, new techniques such as fluorescence histochemistry have evolved into immunohistochemical and more recently in situ hybridization. These techniques have permitted, for the first time, the elucidation of chemically defined neural circuits. Such advances in the mapping of neural systems and the visualization of monoaminergic and peptidergic neurons and their receptors in tissue sections have provided the tools for the burgeoning field of neurochemical pathology of psychiatric disorders. Data provided from such studies has served as the basis for the development of novel pharmacological approaches to the treatment of affective and anxiety disorders, as well as schizophrenia. This review focuses on two major neural systems implicated in the pathophysiology of depression, serotonin and corticotropin-releasing factor (CRF). Development of novel agents are described including selective serotonin receptor agonists, combined selective serotonin receptor antagonists and serotonin reuptake inhibitors, CRF receptor antagonists, and the use of an antisense strategy.

KW - Antisense

KW - Corticotropin-releasing factor (CRF)

KW - Depression

KW - Norepinephrine

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0032192374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032192374&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(98)00068-7

DO - 10.1016/S0006-3223(98)00068-7

M3 - Article

C2 - 9787875

AN - SCOPUS:0032192374

VL - 44

SP - 517

EP - 525

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 7

ER -